More and more research on Ru(II) is a good thingBig pharmas can only wake up as there are growing number of papers that point to where TLT is already an established leader.
Here's another research paper that confirms we're trailblazers by moving into other than platinum-based drugs. Quite impressive that in 2010, TLT dared to go another route than what was so popular in terms of metals and also in terms of technology (PDT versus immunotherapies). TLT's vision is about to pay off in terms of high efficacy, low side effects, low number of doses.
June 2022:
Volume 460, 1
June 2022, 214462
Construction of homo and heteronuclear Ru(II), Ir(III) and Re(I) complexes for target specific cancer therapy Highlights
- •
-
Cancer making it the second most leading cause of death after cardiovascular diseases.
- •
-
Though many platinum-based drugs are currently being used widely in anticancer therapy, the therapeutic value of these complexes comes with severe side effects.
- •
-
Thus, a tremendous amount of research is being carried out on the anticancer activity of other metal complexes to explore their anticancer activity.
- •
-
Herein, we discuss the study of cellular uptake, localisation, mechanism of action and cytotoxicity profiles of several mononuclear and multinuclear ruthenium, iridium and rhenium complexes as potential chemotherapeutic agents.